LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

HomeStock ListAbbVie Inc

AbbVie Inc

Open

Sector Healthcare

162.07 -3.41

Overview

Share price change

24h

Current

Min

159.37

Max

168.65

Key metrics

By Trading Economics

Income

-956M

822M

Sales

374M

14B

P/E

Sector Avg

42.514

23.904

EPS

2.79

Dividend yield

4.394

Profit margin

5.748

Employees

50,000

EBITDA

-433M

6.8B

Recommendations

By TipRanks

Rating Consensus

Buy

12 Months Forecast

+8.33 upside

Dividends

By Dow Jones

Dividend Yield

Sector avg

4.39%

7.76%

Next earnings

26 Apr 2024

Next Dividend date

15 May 2024

Next Ex Dividend date

12 Apr 2024

Market Stats

By TradingEconomics

Market Cap

-17B

302B

Previous open

165.48

Previous close

162.07

News Sentiment

By Acuity

40%

60%

77 / 274 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

AbbVie Inc chart

Related News

25 Mar 2024, 13:43 UTC

Major Market Movers
Acquisitions, Mergers, TakeOvers

Landos Biopharma Shares Surge 178% on Takeover Deal With AbbVie

25 Mar 2024, 13:06 UTC

Acquisitions, Mergers, TakeOvers

AbbVie in Deal to Acquire Landos Biopharma for $137.5 Million

2 Feb 2024, 13:49 UTC

Earnings

Correction to AbbVie Earnings Article Headline

2 Feb 2024, 13:20 UTC

Earnings

AbbVie 4Q Sales Lower as Himura Revenue Sinks

4 Apr 2024, 05:00 UTC

Top News

Big Pharma Stocks Need a Rethink. Investors Keep -2-

4 Apr 2024, 05:00 UTC

Top News

Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake. -- Barrons.com

2 Apr 2024, 12:51 UTC

Earnings

Eli Lilly's Ozempic Competitors Face Risks. Why the Stock Has More Upside. -- Barrons.com

25 Mar 2024, 12:51 UTC

Acquisitions, Mergers, TakeOvers

AbbVie in Deal to Acquire Landos Biopharma for $137.5M

25 Mar 2024, 12:33 UTC

Acquisitions, Mergers, TakeOvers

AbbVie: Proposed Transaction Is Expected to Close in the Second Calendar Qtr of 2024 >ABBV

25 Mar 2024, 12:32 UTC

Acquisitions, Mergers, TakeOvers

AbbVie Will Acquire Landos at a Price of $20.42 Per Shr in Cash Upon Closing, or Approximately $137.5 M in the Aggregate, Plus One Non-Tradable Contingent Value Right Per Shr With a Value of Up to $11.14 Per Shr, or Approximately an Additional $75 M in the Aggregate, Subject to the Achievement of a Clinical Development Milestone >ABBV

25 Mar 2024, 12:32 UTC

Acquisitions, Mergers, TakeOvers

AbbVie: Landos' Lead Investigational Asset Is NX-13, a First-In-Class, Oral NLRX1 Agonist With a Bimodal Mechanism of Action, Which Is Anti-Inflammatory and Facilitates Epithelial Repair >ABBV

25 Mar 2024, 12:32 UTC

Acquisitions, Mergers, TakeOvers

AbbVie Will Acquire Landos at a Price of $20.42 Per Shr in Cash Upon Closing >LABP

25 Mar 2024, 12:31 UTC

Acquisitions, Mergers, TakeOvers

AbbVie to Acquire Landos Biopharma, Further Strengthening Its Portfolio in Inflammatory and Autoimmune Diseases

25 Mar 2024, 12:30 UTC

Acquisitions, Mergers, TakeOvers

AbbVie to Acquire Landos Biopharma, Further Strengthening Its Portfolio in Inflammatory and Autoimmune Diseases >ABBV LABP

12 Feb 2024, 12:53 UTC

Acquisitions, Mergers, TakeOvers

Correct: AbbVie Cuts 1Q View To Adj EPS $2.26-Adj EPS $2.30 >ABBV

12 Feb 2024, 12:51 UTC

Acquisitions, Mergers, TakeOvers

AbbVie's Stock Dips Premarket After It Lowers Q1 Guidance To Reflect Dilutive Impact Of ImmunoGen Deal Close -- MarketWatch

12 Feb 2024, 12:50 UTC

Acquisitions, Mergers, TakeOvers

Correct: AbbVie Cuts 1Q View To Adj EPS $2.26-Adj EPS $2.30 >ABBV

12 Feb 2024, 12:40 UTC

Acquisitions, Mergers, TakeOvers

AbbVie Cuts 1Q View To Adj EPS $2.26-Adj EPS $2.30 >ABBV

12 Feb 2024, 12:39 UTC

Acquisitions, Mergers, TakeOvers

AbbVie Backs FY24 Adj EPS $11.05-Adj EPS $11.25 >ABBV

12 Feb 2024, 12:38 UTC

Acquisitions, Mergers, TakeOvers

AbbVie Completes Acquisition Of ImmunoGen >ABBV IMGN

5 Feb 2024, 12:00 UTC

Top News

What a $200 Billion Blockbuster Drug Reveals About Big Pharma's Playbook -- Heard on the Street -- WSJ

2 Feb 2024, 13:40 UTC

Top News
Earnings

AbbVie Posts Revenue Beat as Humira Sales Tumble. Other Immunology Drugs Are Selling. -- Barrons.com

2 Feb 2024, 13:07 UTC

Market Talk
Earnings

AbbVie's Skyrizi/Rinvoq View Gets Big Boost -- Market Talk

2 Feb 2024, 12:42 UTC

Earnings

AbbVie Raising Its Long-Term Outlook for Skyrizi and Rinvoq Rev; Co Now Expects Combined Skyrizi and Rinvoq 2027 Rev of More Than $27 B >ABBV

2 Feb 2024, 12:40 UTC

Earnings

AbbVie Reaffirms Its Expectations for a High Single-Digit Compound Annual Rev Growth Rate Through 2029 >ABBV

2 Feb 2024, 12:39 UTC

Earnings

AbbVie 4Q Global Venclextra Rev $589M >ABBV

2 Feb 2024, 12:36 UTC

Earnings

AbbVie 4Q Net $822M >ABBV

2 Feb 2024, 12:36 UTC

Earnings

AbbVie 4Q International HUMIRA Rev $564M >ABBV

2 Feb 2024, 12:36 UTC

Earnings

AbbVie 4Q U.S. HUMIRA Rev $2.74B >ABBV

2 Feb 2024, 12:36 UTC

Earnings

AbbVie 4Q Global Net Rev From Oncology Portfolio $1.51B >ABBV

Peer Comparison

Price change

AbbVie Inc forecast

Price Target

By TipRanks

8.33% upside

12 Months Forecast

Average 181.47 USD  8.33%

High 200 USD

Low 135 USD

Based on 17 Wall Street analysts offering 12 month price targets for AbbVie Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

17 ratings

12

Buy

5

Hold

0

Sell

Technical Score

By Trading Central

167.45 / 170 Support&Resistance

Short Team

Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

77 / 274 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Above average

News volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About AbbVie Inc

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.